MogrifyAE will transform the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies.
Mogrify has raised $10.0M in total funding. The most recent round was Series A. The last funding was announced in October 2023.
Mogrify's investors include Ahren Innovation Capital, Parkwalk Advisors, 24 Haymarket, Astellas Venture Management, Aerion Partners.
Mogrify is headquartered in Cambridge, United Kingdom.
MogrifyAE will transform the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies.
Mogrify is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mogrify — Funding & Investors." VCBacked, October 2, 2023, https://www.vcbacked.co/company/mogrify. Accessed October 30, 2026.
VCBacked. (2023). Mogrify — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/mogrify
{{cite web |title=Mogrify — Funding & Investors |url=https://www.vcbacked.co/company/mogrify |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated